BioVaxys Technology Corp.
BIOV
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -116.79% | -204.17% | 114.21% | -27.51% | -92.60% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11,555.56% | 101.27% | -137.33% | 7.06% | 118.68% |
| Change in Net Operating Assets | -643.33% | -72.50% | -74.56% | 95.43% | 432.98% |
| Cash from Operations | 6.52% | -17,988.89% | 220.00% | 91.57% | 96.61% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | 1.14% | -25.06% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7.08% | -28.89% | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | 100.00% | -136.84% | 159.38% | -220.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.74% | -183.11% | 178,425.00% | 101.90% | 33.96% |
